Roche said today it will extend for a second time its tender offer for shares of Spark Therapeutics, the gene therapy developer it wants to acquire for $4.8 billion, as the pharma giant falls further ...
Roche’s $114.50-per-share offer for Spark Therapeutics represents a whopping 122% premium to the gene specialist’s closing price on the last trading day before the acquisition announcement. But some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results